Literature DB >> 34625808

Clinical characteristics and risk factors for COVID-19-associated Candidemia.

Ali S Omrani1,2, Junais Koleri1,2, Fatma Ben Abid1,2, Joanne Daghfel2, Thasneem Odaippurath1,2, Mohamed Zuhail Peediyakkal3, Anas Baiou3, Enas Sarsak1,2, Mahmoud Elayana4, Anvar Kaleeckal5, Muna A Almaslamani1,2.   

Abstract

Patients with COVID-19-associated candidemia (CAC) in an intensive care unit (ICU) were matched 1:2 with those without candidemia, based on ICU admission date and length of stay in ICU being at least equal to that before candidemia in the corresponding case. The incidence rate of CAC was 2.34 per 1000 ICU days. Eighty cases could be matched to appropriate controls. In the multivariate conditional logistic regression analysis, age (P 0.001), and sequential organ failure assessment score (P 0.046) were the only risk factors independently associated with CAC. Tocilizumab and corticosteroids therapy were not independently associated with candidemia. LAY
SUMMARY: In COVID-19 patients who need medical care in an intensive care unit, the risk of developing bloodstream Candida infection is higher in older patients and in those who have a more severe critical illness. Treatment with steroids or tocilizumab does not seem to affect the risk of candida bloodstream infection in these patients.
© The Author(s) 2021. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Entities:  

Keywords:  COVID-19; Coronavirus; candidemia; secondary infection

Mesh:

Substances:

Year:  2021        PMID: 34625808     DOI: 10.1093/mmy/myab056

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  4 in total

1.  COVID-19 and C. auris: A Case-Control Study from a Tertiary Care Center in Lebanon.

Authors:  Fatima Allaw; Sara F Haddad; Nabih Habib; Pamela Moukarzel; Nour Sabiha Naji; Zeina A Kanafani; Ahmad Ibrahim; Nada Kara Zahreddine; Nikolaos Spernovasilis; Garyphallia Poulakou; Souha S Kanj
Journal:  Microorganisms       Date:  2022-05-11

2.  Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant Candida parapsilosis.

Authors:  Antonio Ramos-Martínez; Ilduara Pintos-Pascual; Jesús Guinea; Andrea Gutiérrez-Villanueva; Edith Gutiérrez-Abreu; Judith Díaz-García; Ángel Asensio; Reyes Iranzo; Isabel Sánchez-Romero; María Muñoz-Algarra; Víctor Moreno-Torres; Jorge Calderón-Parra; Elena Múñez; Ana Fernández-Cruz
Journal:  J Fungi (Basel)       Date:  2022-04-27

Review 3.  Fungal Infections in Critically Ill COVID-19 Patients: Inevitabile Malum.

Authors:  Nikoletta Rovina; Evangelia Koukaki; Vasiliki Romanou; Sevasti Ampelioti; Konstantinos Loverdos; Vasiliki Chantziara; Antonia Koutsoukou; George Dimopoulos
Journal:  J Clin Med       Date:  2022-04-04       Impact factor: 4.241

4.  Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19.

Authors:  Deepali Dixit; Polly Jen; Tyler D Maxwell; Steven Smoke; James Andrew McCracken; Maria Cardinale-King; Aditi Haribhakti; Purvi Patel; Eris Cani; Seohyun Claudia Choi; Sugeet Jagpal; Tilly Varughese; Luis L Tatem; Tanaya Bhowmick
Journal:  Crit Care Explor       Date:  2022-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.